VTYX Stock Recent News

The biotech benefits from a much larger peer's recent FDA approval.

Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks, which were one of the worst performers in today's sell-off. With CNBC's Michael Santoli.

ENCINITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will host investor meetings and provide a company overview during fireside chats at the following upcoming investor conferences:

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Yasmeen Rahimi - Piper Sandler Michael Yee - Jefferies Josh Schimmer - Evercore ISI Tiago Fauth - Credit Suisse Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Operator Thank you for standing by and welcome to the Ventyx Biosciences' Second Quarter 2022 Earnings Conference Call. At this time all participants are in listen only mode.

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Marty Auster – Chief Financial Officer Raju Mohan – Founder and Chief Executive Officer Bill Sandborn – President and Chief Medical Officers Conference Call Participants Yasmeen Rahimi – Piper Sandler Josh Schimmer – Evercore ISI Michael Yee – Jefferies Tiago Fauth – Credit Suisse Sam Slutsky – LifeSci Capital Jeff Jones – Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Ventyx Biosciences First Quarter 2022 Financial Results Conference Call.

ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2022 after market close on May 12, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the Barclays Global Healthcare Conference being held March 15-17, 2022.